Mineralys Therapeutics, Common Stock Performance
| MLYS Stock | 15.00 1.15 7.12% |
On a scale of 0 to 100, Mineralys Therapeutics, holds a performance score of 5. The company secures a Beta (Market Risk) of -1.9, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Mineralys Therapeutics, are expected to decrease by larger amounts. On the other hand, during market turmoil, Mineralys Therapeutics, is expected to outperform it. Please check Mineralys Therapeutics,'s value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Mineralys Therapeutics,'s current price movements will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Mineralys Therapeutics, unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (7.12) | Five Day Return (9.64) | Year To Date Return 22.45 | Ten Year Return (18.66) | All Time Return (18.66) |
1 | Disposition of 6349 shares by Rodman David Malcom of Mineralys Therapeutics, at 1.08 subject to Rule 16b-3 | 01/13/2025 |
2 | Disposition of 96815 shares by Adam Levy of Mineralys Therapeutics, at 12.9393 subject to Rule 16b-3 | 01/17/2025 |
3 | Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host ... | 02/05/2025 |
4 | Disposition of 5018 shares by Rodman David Malcom of Mineralys Therapeutics, at 0.54 subject to Rule 16b-3 | 02/07/2025 |
5 | Q4 2024 Mineralys Therapeutics Inc Earnings Call Transcript | 02/13/2025 |
6 | Is Mineralys Therapeutics In A Good Position To Invest In Growth | 02/20/2025 |
7 | Acquisition by Ra Capital Management, L.p. of 32900 shares of Mineralys Therapeutics, at 10.2 subject to Rule 16b-3 | 02/24/2025 |
8 | Mineralys Therapeutics to Announce Topline Data from Launch-HTN and Advance-HTN Pivotal Trials Monday, March 10, 2025, at 800 AM ET | 03/07/2025 |
9 | Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate | 03/10/2025 |
10 | Mineralys Therapeutics Announces Pricing Of 175.0 Million Underwritten Public Offering Of Common Stock - Marketscreener.com | 03/11/2025 |
11 | Mineralys Therapeutics Announces Pricing of 175. ... | 03/12/2025 |
12 | Acquisition by Ra Capital Management, L.p. of 1296296 shares of Mineralys Therapeutics, at 13.5 subject to Rule 16b-3 | 03/13/2025 |
13 | Disposition of 18333 shares by Jon Congleton of Mineralys Therapeutics, at 9.0592 subject to Rule 16b-3 | 03/14/2025 |
14 | Mineralys Therapeutics Announces Closing of Underwriters Option to Purchase Additional Shares ... | 03/18/2025 |
15 | Mineralys Therapeutics, Inc. Among Stocks Receiving the Most Insider Love in March | 03/25/2025 |
| Begin Period Cash Flow | 49.3 M | |
| Free Cash Flow | -166.4 M |
Mineralys |
Mineralys Therapeutics, Relative Risk vs. Return Landscape
If you would invest 1,252 in Mineralys Therapeutics, Common on December 28, 2024 and sell it today you would earn a total of 248.00 from holding Mineralys Therapeutics, Common or generate 19.81% return on investment over 90 days. Mineralys Therapeutics, Common is currently generating 0.5453% in daily expected returns and assumes 7.4583% risk (volatility on return distribution) over the 90 days horizon. In different words, 66% of stocks are less volatile than Mineralys, and 90% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mineralys Therapeutics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mineralys Therapeutics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mineralys Therapeutics, Common, and traders can use it to determine the average amount a Mineralys Therapeutics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0731
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MLYS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 7.46 actual daily | 66 66% of assets are less volatile |
Expected Return
| 0.55 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Mineralys Therapeutics, is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mineralys Therapeutics, by adding it to a well-diversified portfolio.
Mineralys Therapeutics, Fundamentals Growth
Mineralys Stock prices reflect investors' perceptions of the future prospects and financial health of Mineralys Therapeutics,, and Mineralys Therapeutics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mineralys Stock performance.
| Return On Equity | -0.82 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 816.01 M | ||||
| Shares Outstanding | 62.8 M | ||||
| Price To Book | 5.30 X | ||||
| EBITDA | (192.4 M) | ||||
| Net Income | (177.81 M) | ||||
| Total Debt | 14.65 M | ||||
| Book Value Per Share | 3.84 X | ||||
| Cash Flow From Operations | (166.31 M) | ||||
| Earnings Per Share | (3.40) X | ||||
| Market Capitalization | 1.01 B | ||||
| Total Asset | 205.9 M | ||||
| Retained Earnings | (302.52 M) | ||||
| Working Capital | 190.71 M | ||||
About Mineralys Therapeutics, Performance
Assessing Mineralys Therapeutics,'s fundamental ratios provides investors with valuable insights into Mineralys Therapeutics,'s financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Mineralys Therapeutics, is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.86) | (0.91) | |
| Return On Capital Employed | (1.01) | (1.06) | |
| Return On Assets | (0.86) | (0.91) | |
| Return On Equity | (0.93) | (0.88) |
Things to note about Mineralys Therapeutics, performance evaluation
Checking the ongoing alerts about Mineralys Therapeutics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mineralys Therapeutics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mineralys Therapeutics, is way too risky over 90 days horizon | |
| Mineralys Therapeutics, appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (177.81 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Mineralys Therapeutics, generates negative cash flow from operations | |
| Mineralys Therapeutics, has a frail financial position based on the latest SEC disclosures | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Mineralys Therapeutics, Inc. Among Stocks Receiving the Most Insider Love in March |
- Analyzing Mineralys Therapeutics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mineralys Therapeutics,'s stock is overvalued or undervalued compared to its peers.
- Examining Mineralys Therapeutics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mineralys Therapeutics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mineralys Therapeutics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mineralys Therapeutics,'s stock. These opinions can provide insight into Mineralys Therapeutics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mineralys Stock Analysis
When running Mineralys Therapeutics,'s price analysis, check to measure Mineralys Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mineralys Therapeutics, is operating at the current time. Most of Mineralys Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Mineralys Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mineralys Therapeutics,'s price. Additionally, you may evaluate how the addition of Mineralys Therapeutics, to your portfolios can decrease your overall portfolio volatility.